Close
CDMO Safety Testing 2026
Novotech

Clinical Trials

Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response

Johnson & Johnson announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. In addition, the data showed that the durability of the immune...

Mixed Oxford/Pfizer vaccine schedules generate robust immune response against COVID-19, finds Oxford-led study

Alternating doses of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against COVID-19, according to researchers running the University of Oxford-led Com-COV study. In a paper published on the Lancet pre-print server, they report that both โ€˜mixedโ€™ schedules (Pfizer-BioNTech...

CluePoints Launch Post-COVID Trial Assurance Solution

CluePoints, the premier provider ofย Risk-Based Quality Management Solutions for clinical trials, has launched a new Post-COVID Trial Assurance Solution as part of its mission to build safer, more efficient trials for patients, sponsors and, CROs. The pandemic has been the...

Tiziana and FHI Clinical work on Phase II intranasal Covid-19 drug trial

Tiziana Life Sciences plc, a biotechnology company focused on innovative therapeutics for oncology, neurology, inflammation and infectious diseases, announces that it has signed an agreement with FHI Clinical, a global clinical contract research organization (CRO), to conduct a Phase...

Vectura, Incannex Enter Preclinical Services Agreement

Vectura Group plc, an inhalation CDMO, has signed an agreement with Incannex Healthcare Ltd., an Australian cannabinoid medicines development company, to provide preclinical development services for IHL-216A, Incannexโ€™s proprietary inhaled drug product for the treatment of traumatic brain injury...

Phesi data show clinical trial suspensions continue to rise as covid-19 impact on development persists

Analysis from Phesi shows the impact of COVID-19 on clinical development is continuing to mount, with many clinical trial sites unable to bounce back following suspension in March and April 2020. Phesiโ€™s previous analysis in May 2020 found that...

Q2 Solutions and Tasso Collaborate to Provide Unique Solutions for Patients to Accelerate Adoption of Decentralized Clinical Trials

Q2 Solutions, a wholly-owned subsidiary of IQVIA and a leading clinical trial laboratory services organization, announced a transformative collaboration with Tasso Inc., a pioneer in clinical-grade, at-home, patient-centered blood testing, to develop diagnostic tests used in decentralized (virtual) clinical...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate ยป